Insider Buying: Microbix Biosystems Inc (MBX) Director Acquires C$11,600.00 in Stock

Microbix Biosystems Inc (TSE:MBX) Director Martin Marino bought 40,000 shares of Microbix Biosystems stock in a transaction on Tuesday, March 20th. The shares were acquired at an average cost of C$0.29 per share, for a total transaction of C$11,600.00.

MBX stock remained flat at $C$0.28 on Friday. The company had a trading volume of 30,700 shares, compared to its average volume of 44,337. Microbix Biosystems Inc has a twelve month low of C$0.22 and a twelve month high of C$0.40. The stock has a market capitalization of $27.10, a P/E ratio of -28.00 and a beta of -1.95.

How to Become a New Pot Stock Millionaire

Microbix Biosystems (TSE:MBX) last posted its earnings results on Thursday, December 21st. The company reported C($0.01) earnings per share for the quarter. Microbix Biosystems had a negative return on equity of 2.25% and a negative net margin of 3.26%. The business had revenue of C$2.81 million for the quarter.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3296472/insider-buying-microbix-biosystems-inc-mbx-director-acquires-c11600-00-in-stock.html.

About Microbix Biosystems

Microbix Biosystems Inc is a life science company and manufacturer of viral and bacterial antigens and reagents for the diagnostics industry. The Company develops biological products and technologies. The Company operates in two segments: the development, manufacturing and distribution of cell-based products and technology, and the provision of facility, technical and production personnel for contract research and development.

Receive News & Ratings for Microbix Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbix Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Transcontinental  Upgraded to “Outperform” by Royal Bank of Canada
Transcontinental Upgraded to “Outperform” by Royal Bank of Canada
Mosaic Capital  Downgraded to Hold at Canaccord Genuity
Mosaic Capital Downgraded to Hold at Canaccord Genuity
Weibo  Upgraded by Zacks Investment Research to Buy
Weibo Upgraded by Zacks Investment Research to Buy
KeyCorp  Price Target Lowered to $24.00 at BMO Capital Markets
KeyCorp Price Target Lowered to $24.00 at BMO Capital Markets
Wolf Minerals  Sets New 52-Week Low at $2.30
Wolf Minerals Sets New 52-Week Low at $2.30
Omega Diagnostics Group  Trading 0% Higher
Omega Diagnostics Group Trading 0% Higher


© 2006-2018 Ticker Report. Google+.